D-0060-2023 Class II Terminated

Recalled by ImprimisRx NJ — Ledgewood, NJ

FDA drug recall D-0060-2023 was initiated by ImprimisRx NJ on Nov 9, 2022 and is designated Class II. Reason for recall: Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost. The recall status is terminated (terminated Aug 23, 2023). Affected quantity: 960 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 23, 2022
Initiation Date
Nov 9, 2022
Termination Date
Aug 23, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
960 bottles

Product description

Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.

Reason for recall

Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.

Distribution pattern

Nationwide in the USA

Code information

Lot # 06272022@3, Exp. date 11/24/2022 Lot # 08302022@1, Exp. date 01/27/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0060-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0060-2023. Report a data issue: hello@regdatalab.com.